Efficacy and Safety of Cabozantinib in Patients With Hepatocellular Carcinoma

Summary

This is an open-label, single-center, Phase II trial designed to estimate in terms of PFS the efficacy of cabozantinib, given as second- or third- line treatment in HCC patients that progress on or are intolerant to immune checkpoint inhibitors, including anti-PD-1 and anti-PD-L1 antibodies.

Timeline

Start

2020-01-30

Primary completion

2023-06

Completion

2023-09

Drugs

Indications